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Inflammatory Muscle Diseases
To the Editor: In the review article on inflammatory muscle diseases, Dalakas (April 30 issue)1
outlines four major subtypes. In 1998, Gherardi
et al. described a new but underrecognized clinical variant, called macrophagic myofasciitis,2 a
condition that presents as diffuse myalgias of
variable intensity associated with chronic fatigue. Myalgia predominantly affects the lower
limbs and is often aggravated by exercise. It is
associated with arthralgias in 50 to 60% of patients, as well as fever in 30% of patients.3 Results on electromyography may be myopathic,
and creatine kinase levels may be elevated in up
to 50% of patients.4 This disease is associated
with intramuscular injection of aluminum hydroxide, which is used as an adjuvant in several
vaccines (hepatitis A and B).3 Muscle biopsy, including the fascia, at the site of the immunization reveals a pathognomonic focal macrophage
infiltration with intracytoplasmic crystalline inclusions corresponding to aluminum deposits.2
This picture is part of the inflammatory autoimmune syndrome induced by adjuvants.5
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a 10-year survival rate of 55% among patients
with polymyositis and 53% among those with
dermatomyositis.1 In 2012, Schiopu et al. reported a 10-year survival rate of 62% in inflammatory
myopathies.2 In 2014, Aggarwal et el. reported a
10-year survival rate of 70% among patients with
a positive autoantibody response to histidyl-transfer RNA synthetase (Jo-1) and 50% among patients with a negative response.3 Taborda et al.
reported a 10-year survival rate of more than 90%
in the United Kingdom,4 as cited by Dalakas. In
general, the mean 10-year survival rate among
patients with inflammatory myopathies from the
cited four studies is approximately 69%, a rate
that might be affected by ethnic group, serologic
presentation, and disease severity. Moreover, in
patients in whom the myopathy is associated
with cancer, the prognosis is even worse. Though
diagnostic methods and therapies have improved,
we should avoid being overly optimistic about the
prognosis.
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To the Editor: We are concerned about the DOI: 10.1056/NEJMc1506827
statement in the review article by Dalakas that
the long-term outcome of inflammatory myop- The author replies: Young et al. refer to a macathies has improved, with “a 10-year survival rate rophage-mediated inflammatory disorder that
of more than 90%.” In 2006, Airio et al. reported affects muscle fascia but not myofibers that are
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remote from the macrophagic infiltrates.1 In contrast to inflammatory muscle diseases, macrophagic myofasciitis presents with myalgia and
chronic fatigue but not muscle weakness, has focal histopathological features that are limited to
the fascia and occasionally perifascicular fibers
of deltoid muscles in sites of previous vaccinations, and is predominantly, if not exclusively, seen
in France, where the deltoid muscles (used for
vaccinations) are routinely preferred for diagnostic biopsies.1 Macrophagic myofasciitis is a seemingly toxic fasciitis, not a primary inflammatory
muscle disease, that is linked to aluminum-containing substrates in some vaccines, similar to
the eosinophilia–myalgia syndrome caused by
adulterated L-tryptophan.2 Whether these focal
fascial macrophagic collections are incidental
reactions to the injected vaccines or trigger the
reported systemic symptoms of fatigue, myalgia,
and cognitive dysfunction remains unclear. The
proposed hypothesis that there is an autoimmune
or inflammatory syndrome induced by adjuvants
is beyond the scope of my review.
Chen et al. refer to survival rates in four different studies with heterogeneous diagnostic
criteria that have not been adjusted for systemic
conditions or systematically applied immunotherapies. Thus, lumping the rates into one group
to obtain a mean survival rate is not appropriate.
The study they cite by Airio et al. refers to patients who were evaluated 30 to 46 years ago,
whereas the study they cite by Aggarwal et al.
was limited to patients with Jo-1 antibodies who
often have interstitial lung disease. The reference
that I cited (in spite of its limitations) is more
representative because it includes patients from
one center in which practitioners were experienced in modern immunotherapies. Improved
supportive care and the application of new therapies, such as intravenous immune globulin and
rituximab, probably account for improved rates
of survival. A life expectancy of 81 years was
reportedly normal even for patients with inclusion-body myositis, the most disabling of the
myositis subtypes.3 The numbers of patients who
were included in these studies are arguably small,
and we need better survival studies that take
into consideration various factors including correct diagnosis (ensuring specific rates for each
disease subtype), the patient’s age at onset, the
presence of cancer or pulmonary involvement,
the time from the initiation of therapy, disease
severity, and the judicious use of immunothera394
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pies and good supportive care. I hope that the
data in my review article will lead to increased
diagnostic accuracy, early initiation of more effective immunotherapies, and higher survival rates.
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